Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MEI Pharma (MEIP)

MEI Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MEIP
DateTimeSourceHeadlineSymbolCompany
31/01/202521:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
20/12/202422:20Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:MEIPMEI Pharma Inc
20/12/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MEIPMEI Pharma Inc
20/12/202422:10Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MEIPMEI Pharma Inc
25/11/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
14/11/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
12/11/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MEIPMEI Pharma Inc
12/11/202421:05Business WireMEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionNASDAQ:MEIPMEI Pharma Inc
25/10/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
19/09/202421:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MEIPMEI Pharma Inc
19/09/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
19/09/202420:01Business WireMEI Pharma Reports Fiscal Year End 2024 Cash PositionNASDAQ:MEIPMEI Pharma Inc
12/08/202412:30Business WireMEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesNASDAQ:MEIPMEI Pharma Inc
02/08/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
30/07/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
22/07/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
22/07/202420:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MEIPMEI Pharma Inc
22/07/202412:30Business WireMEI Pharma to Consider Strategic AlternativesNASDAQ:MEIPMEI Pharma Inc
21/05/202420:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
21/05/202417:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
20/05/202420:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MEIPMEI Pharma Inc
09/05/202420:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
09/05/202420:02Business WireMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsNASDAQ:MEIPMEI Pharma Inc
09/05/202420:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MEIPMEI Pharma Inc
11/04/202412:02Business WireMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344NASDAQ:MEIPMEI Pharma Inc
11/04/202412:00Business WireMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsNASDAQ:MEIPMEI Pharma Inc
10/04/202412:00Business WireMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:MEIPMEI Pharma Inc
26/03/202412:00Business WireMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaNASDAQ:MEIPMEI Pharma Inc
29/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MEIPMEI Pharma Inc
21/02/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MEIPMEI Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:MEIP